<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Adhera Therapeutics Inc. — News on 6ix</title>
<link>https://6ix.com/company/adhera-therapeutics-inc</link>
<description>Latest news and press releases for Adhera Therapeutics Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 25 Jan 2023 14:03:06 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/adhera-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835497678dffbe2df0e443b.webp</url>
<title>Adhera Therapeutics Inc.</title>
<link>https://6ix.com/company/adhera-therapeutics-inc</link>
</image>
<item>
<title>Adhera Therapeutics to Collaborate with Alberta Diabetes Institute, University of Alberta to Initiate Clinical Trial of MLR-1023 in Type 1 Diabetes</title>
<link>https://6ix.com/company/adhera-therapeutics-inc/news/adhera-therapeutics-to-collaborate-with-alberta-diabetes-institute-university-of-alberta-to-initiate-clinical-trial-of-mlr-1023-in-type-1-diabetes</link>
<guid isPermaLink="true">https://6ix.com/company/adhera-therapeutics-inc/news/adhera-therapeutics-to-collaborate-with-alberta-diabetes-institute-university-of-alberta-to-initiate-clinical-trial-of-mlr-1023-in-type-1-diabetes</guid>
<pubDate>Wed, 25 Jan 2023 14:03:06 GMT</pubDate>
<description>Adhera Therapeutics to Collaborate with Alberta Diabetes Institute, University of Alberta to Initiate Clinical Trial of MLR-1023 in Type 1 Diabetes.</description>
</item>
<item>
<title>Adhera Therapeutics Announces CEO, Senior Management Changes, Plans for NASDAQ Uplist</title>
<link>https://6ix.com/company/adhera-therapeutics-inc/news/adhera-therapeutics-announces-ceo-senior-management-changes-plans-for-nasdaq-uplist</link>
<guid isPermaLink="true">https://6ix.com/company/adhera-therapeutics-inc/news/adhera-therapeutics-announces-ceo-senior-management-changes-plans-for-nasdaq-uplist</guid>
<pubDate>Mon, 19 Sep 2022 13:15:39 GMT</pubDate>
<description>Adhera Therapeutics Announces CEO, Senior Management Changes, Plans for NASDAQ Uplist.</description>
</item>
<item>
<title>Adhera Therapeutics Signs Letter of Intent to Acquire CD71-Targeted Cancer Therapy Paclitaxel Gallium Transferrin</title>
<link>https://6ix.com/company/adhera-therapeutics-inc/news/adhera-therapeutics-signs-letter-of-intent-to-acquire-cd71-targeted-cancer-therapy-paclitaxel-gallium-transferrin</link>
<guid isPermaLink="true">https://6ix.com/company/adhera-therapeutics-inc/news/adhera-therapeutics-signs-letter-of-intent-to-acquire-cd71-targeted-cancer-therapy-paclitaxel-gallium-transferrin</guid>
<pubDate>Tue, 19 Jul 2022 13:15:39 GMT</pubDate>
<description>Adhera Therapeutics Signs Letter of Intent to Acquire CD71-Targeted Cancer Therapy Paclitaxel Gallium Transferrin.</description>
</item>
<item>
<title>Adhera Therapeutics Appoints Trond K. Waerness as Chairman of the Board, Company Focuses on Uplist to NASDAQ</title>
<link>https://6ix.com/company/adhera-therapeutics-inc/news/adhera-therapeutics-appoints-trond-k-waerness-as-chairman-of-the-board-company-focuses-on-uplist-to-nasdaq</link>
<guid isPermaLink="true">https://6ix.com/company/adhera-therapeutics-inc/news/adhera-therapeutics-appoints-trond-k-waerness-as-chairman-of-the-board-company-focuses-on-uplist-to-nasdaq</guid>
<pubDate>Thu, 19 May 2022 13:16:12 GMT</pubDate>
<description>Adhera Therapeutics Appoints Trond K. Waerness as Chairman of the Board, Company Focuses on Uplist to NASDAQ.</description>
</item>
<item>
<title>Adhera Therapeutics Names Preeminent Diabetes Pioneer Dr. Jean Buteau to Scientific Advisory Board</title>
<link>https://6ix.com/company/adhera-therapeutics-inc/news/adhera-therapeutics-names-preeminent-diabetes-pioneer-dr-jean-buteau-to-scientific-advisory-board</link>
<guid isPermaLink="true">https://6ix.com/company/adhera-therapeutics-inc/news/adhera-therapeutics-names-preeminent-diabetes-pioneer-dr-jean-buteau-to-scientific-advisory-board</guid>
<pubDate>Mon, 21 Mar 2022 13:38:08 GMT</pubDate>
<description>Adhera Therapeutics Names Preeminent Diabetes Pioneer Dr. Jean Buteau to Scientific Advisory Board.</description>
</item>
<item>
<title>OTC Markets Group Welcomes New OTCQB Companies – January 24</title>
<link>https://6ix.com/company/adhera-therapeutics-inc/news/otc-markets-group-welcomes-new-otcqb-companies-january-24</link>
<guid isPermaLink="true">https://6ix.com/company/adhera-therapeutics-inc/news/otc-markets-group-welcomes-new-otcqb-companies-january-24</guid>
<pubDate>Mon, 24 Jan 2022 12:00:00 GMT</pubDate>
<description>OTC Markets Group Welcomes New OTCQB Companies – January 24.</description>
</item>
<item>
<title>Adhera Therapeutics Announces Uplisting to OTCQB Venture Marketplace</title>
<link>https://6ix.com/company/adhera-therapeutics-inc/news/adhera-therapeutics-announces-uplisting-to-otcqb-venture-marketplace</link>
<guid isPermaLink="true">https://6ix.com/company/adhera-therapeutics-inc/news/adhera-therapeutics-announces-uplisting-to-otcqb-venture-marketplace</guid>
<pubDate>Thu, 20 Jan 2022 13:46:39 GMT</pubDate>
<description>Adhera Therapeutics Announces Uplisting to OTCQB Venture Marketplace.</description>
</item>
<item>
<title>Adhera Therapeutics Announces Third Quarter 2019 Financial Results and Operational Highlights</title>
<link>https://6ix.com/company/adhera-therapeutics-inc/news/adhera-therapeutics-announces-third-quarter-2019-financial-results-and-operational-highlights</link>
<guid isPermaLink="true">https://6ix.com/company/adhera-therapeutics-inc/news/adhera-therapeutics-announces-third-quarter-2019-financial-results-and-operational-highlights</guid>
<pubDate>Tue, 19 Nov 2019 21:16:48 GMT</pubDate>
<description>Adhera Therapeutics Announces Third Quarter 2019 Financial Results and Operational Highlights.</description>
</item>
<item>
<title>Adhera Therapeutics Announces Termination of Tender Offer for Preferred Stock</title>
<link>https://6ix.com/company/adhera-therapeutics-inc/news/adhera-therapeutics-announces-termination-of-tender-offer-for-preferred-stock</link>
<guid isPermaLink="true">https://6ix.com/company/adhera-therapeutics-inc/news/adhera-therapeutics-announces-termination-of-tender-offer-for-preferred-stock</guid>
<pubDate>Thu, 26 Sep 2019 20:28:40 GMT</pubDate>
<description>Adhera Therapeutics Announces Termination of Tender Offer for Preferred Stock.</description>
</item>
<item>
<title>Adhera Therapeutics and Indegene Announce Next Gen Commercialization Partnership</title>
<link>https://6ix.com/company/adhera-therapeutics-inc/news/adhera-therapeutics-and-indegene-announce-next-gen-commercialization-partnership</link>
<guid isPermaLink="true">https://6ix.com/company/adhera-therapeutics-inc/news/adhera-therapeutics-and-indegene-announce-next-gen-commercialization-partnership</guid>
<pubDate>Tue, 10 Sep 2019 14:22:05 GMT</pubDate>
<description>Adhera Therapeutics and Indegene Announce Next Gen Commercialization Partnership.</description>
</item>
<item>
<title>Adhera and Allegis Pharma Announce Co-Promotion Agreement </title>
<link>https://6ix.com/company/adhera-therapeutics-inc/news/adhera-and-allegis-pharma-announce-co-promotion-agreement</link>
<guid isPermaLink="true">https://6ix.com/company/adhera-therapeutics-inc/news/adhera-and-allegis-pharma-announce-co-promotion-agreement</guid>
<pubDate>Fri, 06 Sep 2019 11:30:53 GMT</pubDate>
<description>Adhera and Allegis Pharma Announce Co-Promotion Agreement.</description>
</item>
<item>
<title>Adhera Therapeutics Announces Termination of Tender Offer for Warrants</title>
<link>https://6ix.com/company/adhera-therapeutics-inc/news/adhera-therapeutics-announces-termination-of-tender-offer-for-warrants</link>
<guid isPermaLink="true">https://6ix.com/company/adhera-therapeutics-inc/news/adhera-therapeutics-announces-termination-of-tender-offer-for-warrants</guid>
<pubDate>Tue, 02 Jul 2019 20:33:12 GMT</pubDate>
<description>Adhera Therapeutics Announces Termination of Tender Offer for Warrants.</description>
</item>
<item>
<title>Adhera Therapeutics Appoints Nancy Phelan as Chief Executive Officer</title>
<link>https://6ix.com/company/adhera-therapeutics-inc/news/adhera-therapeutics-appoints-nancy-phelan-as-chief-executive-officer</link>
<guid isPermaLink="true">https://6ix.com/company/adhera-therapeutics-inc/news/adhera-therapeutics-appoints-nancy-phelan-as-chief-executive-officer</guid>
<pubDate>Thu, 04 Apr 2019 13:17:12 GMT</pubDate>
<description>Adhera Therapeutics Appoints Nancy Phelan as Chief Executive Officer.</description>
</item>
<item>
<title>Adhera Therapeutics and Alyvant Enter into Digital Co-Promotion Agreement for Prestalia</title>
<link>https://6ix.com/company/adhera-therapeutics-inc/news/adhera-therapeutics-and-alyvant-enter-into-digital-co-promotion-agreement-for-prestalia</link>
<guid isPermaLink="true">https://6ix.com/company/adhera-therapeutics-inc/news/adhera-therapeutics-and-alyvant-enter-into-digital-co-promotion-agreement-for-prestalia</guid>
<pubDate>Mon, 04 Mar 2019 13:14:01 GMT</pubDate>
<description>Adhera Therapeutics and Alyvant Enter into Digital Co-Promotion Agreement for Prestalia.</description>
</item>
<item>
<title>Adhera Therapeutics' DyrctAxessTM Platform Helps 78% of Patients Adhere to PRESTALIA(R); Achieves Exceptionally High Level of Drug Adherence to an Antihypertensive Medication</title>
<link>https://6ix.com/company/adhera-therapeutics-inc/news/adhera-therapeutics-dyrctaxesstm-platform-helps-78percent-of-patients-adhere-to-prestaliar-achieves-exceptionally-high-level-of-drug-adherence-to-an-antihypertensive-medication</link>
<guid isPermaLink="true">https://6ix.com/company/adhera-therapeutics-inc/news/adhera-therapeutics-dyrctaxesstm-platform-helps-78percent-of-patients-adhere-to-prestaliar-achieves-exceptionally-high-level-of-drug-adherence-to-an-antihypertensive-medication</guid>
<pubDate>Wed, 06 Feb 2019 13:02:34 GMT</pubDate>
<description>Adhera Therapeutics' DyrctAxessTM Platform Helps 78% of Patients Adhere to PRESTALIA(R); Achieves Exceptionally High Level of Drug Adherence to an Antihypertensive Medication.</description>
</item>
<item>
<title>Adhera Therapeutics Provides Third Quarter 2018 Financial Results and Business Update</title>
<link>https://6ix.com/company/adhera-therapeutics-inc/news/adhera-therapeutics-provides-third-quarter-2018-financial-results-and-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/adhera-therapeutics-inc/news/adhera-therapeutics-provides-third-quarter-2018-financial-results-and-business-update</guid>
<pubDate>Wed, 21 Nov 2018 00:09:41 GMT</pubDate>
<description>Adhera Therapeutics Provides Third Quarter 2018 Financial Results and Business Update.</description>
</item>
<item>
<title>Adhera Therapeutics Selects IQVIA’s OCE Technology Platform to Support Commercial Excellence</title>
<link>https://6ix.com/company/adhera-therapeutics-inc/news/adhera-therapeutics-selects-iqvias-oce-technology-platform-to-support-commercial-excellence</link>
<guid isPermaLink="true">https://6ix.com/company/adhera-therapeutics-inc/news/adhera-therapeutics-selects-iqvias-oce-technology-platform-to-support-commercial-excellence</guid>
<pubDate>Tue, 20 Nov 2018 13:03:12 GMT</pubDate>
<description>Adhera Therapeutics Selects IQVIA’s OCE Technology Platform to Support Commercial Excellence.</description>
</item>
<item>
<title>Marina Biotech Appoints Nancy R. Phelan to the Board of Directors</title>
<link>https://6ix.com/company/adhera-therapeutics-inc/news/marina-biotech-appoints-nancy-r-phelan-to-the-board-of-directors</link>
<guid isPermaLink="true">https://6ix.com/company/adhera-therapeutics-inc/news/marina-biotech-appoints-nancy-r-phelan-to-the-board-of-directors</guid>
<pubDate>Wed, 03 Oct 2018 12:08:29 GMT</pubDate>
<description>Marina Biotech Appoints Nancy R. Phelan to the Board of Directors.</description>
</item>
<item>
<title>Marina Biotech Appoints Eric Teague as Chief Financial Officer</title>
<link>https://6ix.com/company/adhera-therapeutics-inc/news/marina-biotech-appoints-eric-teague-as-chief-financial-officer</link>
<guid isPermaLink="true">https://6ix.com/company/adhera-therapeutics-inc/news/marina-biotech-appoints-eric-teague-as-chief-financial-officer</guid>
<pubDate>Mon, 24 Sep 2018 12:07:28 GMT</pubDate>
<description>Marina Biotech Appoints Eric Teague as Chief Financial Officer.</description>
</item>
<item>
<title>Marina Biotech Appoints Jay D. Schwartz to serve as Senior Vice President, Commercial Operations</title>
<link>https://6ix.com/company/adhera-therapeutics-inc/news/marina-biotech-appoints-jay-d-schwartz-to-serve-as-senior-vice-president-commercial-operations</link>
<guid isPermaLink="true">https://6ix.com/company/adhera-therapeutics-inc/news/marina-biotech-appoints-jay-d-schwartz-to-serve-as-senior-vice-president-commercial-operations</guid>
<pubDate>Mon, 06 Aug 2018 13:18:41 GMT</pubDate>
<description>Marina Biotech Appoints Jay D. Schwartz to serve as Senior Vice President, Commercial Operations.</description>
</item>
</channel>
</rss>